Theriva Biologics (NYSEAMERICAN:TOVX) Stock Price Up 0.7% – Here’s Why

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) shares traded up 0.7% during trading on Monday . The company traded as high as $0.2572 and last traded at $0.2529. 1,084,006 shares traded hands during mid-day trading, a decline of 93% from the average daily volume of 16,082,195 shares. The stock had previously closed at $0.2511.

Analyst Ratings Changes

Separately, Maxim Group upgraded Theriva Biologics from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a research note on Tuesday, March 31st. One investment analyst has rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $1.00.

Theriva Biologics Price Performance

The company has a quick ratio of 1.63, a current ratio of 1.63 and a debt-to-equity ratio of 0.11. The firm’s fifty day moving average price is $0.30 and its 200 day moving average price is $0.24. The stock has a market cap of $8.06 million, a PE ratio of -0.01 and a beta of 1.10.

Theriva Biologics (NYSEAMERICAN:TOVX) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.05) earnings per share (EPS) for the quarter. The business had revenue of $0.30 million for the quarter.

Institutional Investors Weigh In On Theriva Biologics

An institutional investor recently bought a new position in Theriva Biologics stock. Two Sigma Investments LP acquired a new position in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 61,837 shares of the company’s stock, valued at approximately $25,000. Two Sigma Investments LP owned about 0.64% of Theriva Biologics at the end of the most recent reporting period. 6.17% of the stock is currently owned by hedge funds and other institutional investors.

Theriva Biologics Company Profile

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.